CHICAGO--(BUSINESS WIRE)--New physician guidelines now recommend use of contrast-enhanced ultrasound (CEUS) to diagnose hepatocellular carcinoma (HCC), the most common primary liver cancer.

芝加哥-（商业信息）-新的医生指南现在推荐使用对比增强超声（CEUS）来诊断肝细胞癌（HCC），这是最常见的原发性肝癌。

CEUS is a relatively simple, low-cost, non-invasive diagnostic imaging modality that is safely and routinely used worldwide to enhance conventional diagnostic ultrasound imaging, according to the International Contrast Ultrasound Society (ICUS), a nonprofit medical society that offers free CME-accredited webinars on CEUS and other services for the global CEUS community..

根据国际造影超声学会（ICUS）的资料，CEUS是一种相对简单，低成本，无创的诊断成像模式，在全球范围内安全常规地用于增强常规诊断超声成像，ICUS是一家为全球CEUS社区提供免费CME认证的CEUS和其他服务网络研讨会。。

“Recent studies demonstrate sufficiently high test performance for CEUS as a diagnostic modality,” according to the new Practice Guidance on Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma published by the American Society for the Study of Liver Disease (AASLD).

根据美国肝病研究学会（AASLD）发布的关于预防，诊断和治疗肝细胞癌的新实践指南，“最近的研究表明，CEUS作为一种诊断方式具有足够高的测试性能”。

The new guidelines recommend CEUS for diagnosing HCC when MR and CT are inconclusive, unavailable or contraindicated.

当MR和CT不确定，不可用或禁忌时，新指南建议CEUS诊断HCC。

Liver cancer is the third leading cause of cancer-related deaths, and HCC disproportionately affects American Indian, Hispanic and Black patients when compared to non-Hispanic White persons, according to AASLD.

根据AASLD，肝癌是癌症相关死亡的第三大原因，与非西班牙裔白人相比，HCC对美洲印第安人，西班牙裔和黑人患者的影响不成比例。

“We are concerned that without access to CEUS, minority patients with limited access to alternative imaging may be at even greater risk for misdiagnosis or missed diagnosis,” said Dr. Yuko Kono, a professor of radiology and medicine at the University of California San Diego. Dr. Kono is a past chair of the American College of Radiology Liver Imaging & Reporting Data Systems (LI-RADS) CEUS Working Group and is a member of the board of directors of ICUS..

加州大学圣地亚哥分校放射学和医学教授Yuko Kono博士说：“我们担心，如果无法获得CEUS，少数患者获得替代成像的机会有限，可能会有更大的误诊或漏诊的风险。”迭戈。Kono博士是美国放射学会肝脏成像和报告数据系统（LI-RADS）CEUS工作组的前任主席，也是ICU董事会成员。。

CEUS uses FDA-approved “microbubble” ultrasound contrast agents (UCAs) that are administered intravenously during an ultrasound scan. UCAs do not contain dye, create no known risk of kidney damage or deposit of contrast media in the brain, and do not expose patients or hospital staff to ionizing radiation..

CEUS使用FDA批准的“微泡”超声造影剂（UCA），在超声扫描期间静脉内给药。UCA不含染料，不会造成肾脏损害或大脑中造影剂沉积的已知风险，也不会使患者或医院工作人员接触电离辐射。。

CEUS may be used to identify and characterize tumors, monitor chronic gastro-intestinal diseases, diagnose heart and vascular disease, evaluate other serious medical conditions and monitor therapy.

CEUS可用于识别和表征肿瘤，监测慢性胃肠疾病，诊断心脏和血管疾病，评估其他严重的医疗状况和监测治疗。

“CEUS scans are very reliable for HCC diagnosis, with accuracy equivalent to MR and CT,” according to Dr. Andrej Lyshchik, a professor of radiology at Thomas Jefferson University in Philadelphia. Dr. Lyshchik currently chairs the ACR LI-RADS CEUS Working Group and is a member of both the LI-RADS Steering Committee and the board of directors of ICUS..

费城托马斯·杰斐逊大学放射学教授Andrej Lyshchik博士说：“CEUS扫描对于HCC诊断非常可靠，准确度相当于MR和CT。”。Lyshchik博士目前担任ACR LI-RADS CEUS工作组主席，并且是LI-RADS指导委员会和ICU董事会的成员。。

He said that CEUS also is safer and less expensive than alternative forms of diagnostic imaging, and it provides diagnostic information in real time.

他说，CEUS也比其他形式的诊断成像更安全，更便宜，并且可以实时提供诊断信息。

“In some cases, CEUS can avoid delays associated with MR or CT, and that can help speed up the patient’s access to appropriate therapy,” Dr. Lyshchik added.

Lyshchik博士补充说：“在某些情况下，CEUS可以避免与MR或CT相关的延迟，这有助于加快患者获得适当治疗的速度。”。

AASLD guidelines are widely followed by physicians throughout North America, and the new CEUS recommendations “represent an important and appropriate step forward in integrating CEUS into modern imaging labs,” said Kono.

Kono说，北美各地的医生都广泛遵循AASLD指南，新的CEUS建议“是将CEUS整合到现代成像实验室中迈出的重要而适当的一步”。

CEUS is also recommended by guidelines promulgated by professional societies around the world, according to Dr. Fabio Piscaglia, a professor of internal medicine at the University of Bologna and a past president of the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB).

博洛尼亚大学内科教授，欧洲超声医学和生物学学会联合会前任主席Fabio Piscaglia博士说，世界各地专业协会颁布的指南也推荐CEUS（EFSUMB）。

Dr. Piscaglia also is first author of the EFSUMB guidelines on non-hepatic clinical applications of CEUS, a co-author of HCC guidelines of the European Association of the Study of Liver, and a board member of ICUS..

Piscaglia博士也是CEUS非肝脏临床应用EFSUMB指南的第一作者，CEUS是欧洲肝脏研究协会HCC指南的共同作者，也是ICU的董事会成员。。

“CEUS is a very reliable, safe, low-cost diagnostic modality that improves patient outcomes and experiences, and often saves lives,” Dr. Piscaglia said.

Piscaglia博士说：“CEUS是一种非常可靠，安全，低成本的诊断方式，可以改善患者的治疗效果和经验，并经常挽救生命。”。

UCAs are manufactured and sold in the US and elsewhere by Bracco, Lantheus and GE Healthcare.

UCA由Bracco，Lantheus和GE Healthcare在美国和其他地方制造和销售。

ABOUT ICUS:

关于ICU：

The International Contrast Ultrasound Society (ICUS) is a nonprofit medical society dedicated to advancing the safe and medically appropriate use of contrast enhanced ultrasound (CEUS) to improve patient care globally. Membership in ICUS is available free of charge and there is no fee for ICUS CME-accredited educational programs, newsletters or other resources..

国际造影超声学会（ICUS）是一家非营利性医学会，致力于促进造影增强超声（CEUS）的安全和医学适当使用，以改善全球患者护理。ICU会员可免费获得，ICU CME认证的教育计划，新闻通讯或其他资源不收费。。

To join ICUS and learn more about CEUS, download ICUS Connect and visit the ICUS website (www.icus-society.org).

要加入ICU并了解有关CEUS的更多信息，请下载ICU连接并访问ICU网站（www.ICUS-society.org）。